Hangzhou Biotest Biotech Co Ltd (688767) - Total Assets
Based on the latest financial reports, Hangzhou Biotest Biotech Co Ltd (688767) holds total assets worth CN¥2.49 Billion CNY (≈ $363.78 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 688767 cash flow conversion for how efficiently the company converts equity into cash flow.
Hangzhou Biotest Biotech Co Ltd - Total Assets Trend (2017–2025)
This chart illustrates how Hangzhou Biotest Biotech Co Ltd's total assets have evolved over time, based on quarterly financial data. See Hangzhou Biotest Biotech Co Ltd (688767) share price today for real-time trading data and today's change.
Hangzhou Biotest Biotech Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Hangzhou Biotest Biotech Co Ltd's total assets of CN¥2.49 Billion consist of 65.4% current assets and 34.6% non-current assets. Explore working capital position of Hangzhou Biotest Biotech Co Ltd to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 58.1% |
| Accounts Receivable | CN¥89.37 Million | 3.5% |
| Inventory | CN¥69.68 Million | 2.7% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥269.31 Million | 10.6% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Hangzhou Biotest Biotech Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hangzhou Biotest Biotech Co Ltd's current assets represent 65.4% of total assets in 2025, an increase from 52.0% in 2017.
- Cash Position: Cash and equivalents constituted 58.1% of total assets in 2025, up from 7.0% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, a decrease from 17.0% in 2017.
- Asset Diversification: The largest asset category is intangible assets at 10.6% of total assets.
Hangzhou Biotest Biotech Co Ltd Competitors by Total Assets
Key competitors of Hangzhou Biotest Biotech Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $2.19 Billion |
|
Dyne Therapeutics Inc
NASDAQ:DYN
|
USA | $1.08 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Recursion Pharmaceuticals Inc
NASDAQ:RXRX
|
USA | $1.21 Billion |
|
LegoChem Biosciences Inc
KQ:141080
|
Korea | ₩652.93 Billion |
Hangzhou Biotest Biotech Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 14.11 | 16.74 | 3.10 |
| Quick Ratio | 13.47 | 16.05 | 2.79 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.47 Billion | CN¥1.71 Billion | CN¥795.61 Million |
Hangzhou Biotest Biotech Co Ltd - Advanced Valuation Insights
This section examines the relationship between Hangzhou Biotest Biotech Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.46 |
| Latest Market Cap to Assets Ratio | 0.34 |
| Asset Growth Rate (YoY) | -2.4% |
| Total Assets | CN¥2.54 Billion |
| Market Capitalization | $865.35 Million USD |
Valuation Analysis
Below Book Valuation: The market values Hangzhou Biotest Biotech Co Ltd's assets below their book value (0.34x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Hangzhou Biotest Biotech Co Ltd's assets decreased by 2.4% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Hangzhou Biotest Biotech Co Ltd (2017–2025)
The table below shows the annual total assets of Hangzhou Biotest Biotech Co Ltd from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.54 Billion ≈ $371.60 Million |
-2.41% |
| 2024-12-31 | CN¥2.60 Billion ≈ $380.77 Million |
+0.87% |
| 2023-12-31 | CN¥2.58 Billion ≈ $377.47 Million |
-6.24% |
| 2022-12-31 | CN¥2.75 Billion ≈ $402.59 Million |
+13.15% |
| 2021-12-31 | CN¥2.43 Billion ≈ $355.81 Million |
+283.57% |
| 2020-12-31 | CN¥633.92 Million ≈ $92.76 Million |
+201.23% |
| 2019-12-31 | CN¥210.44 Million ≈ $30.79 Million |
+36.09% |
| 2018-12-31 | CN¥154.63 Million ≈ $22.63 Million |
+21.27% |
| 2017-12-31 | CN¥127.52 Million ≈ $18.66 Million |
-- |
About Hangzhou Biotest Biotech Co Ltd
Hangzhou Biotest Biotech Co.,Ltd. engages in the research and development, manufacture, sale, and service of in vitro diagnostic assays and reagents, and instruments in China and internationally. The company offers medical test products for fertility health, cardiology, oncology, inflammation, veterinary test, drug of abuse, infectious diseases, and other diagnostic rapid test. It also provides m… Read more